Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0000899243-21-004959)

Filing Details

Accession Number:: 0000899243-21-004959
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-02-04 17:47:33
Reporting Period:: 2021-02-03

Accepted Time:: 2021-02-04 17:47:33
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1701541	Black Diamond Therapeutics Inc.	BDTX	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1788368	D. Christopher Roberts	C/O Black Diamond Therapeutics, Inc. One Main Street, 10Th Floor Cambridge MA 02142	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-02-03	2,500	$10.86	5,700	No	4	M	Direct
Common Stock	Disposition	2021-02-03	2,500	$25.35	3,200	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-02-03	2,500	$0.00	2,500	$10.86

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
171,109		2029-09-08	No	4	M	Direct

Footnotes

Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020.
25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter.